Scancell Ltd is a clinical-stage immunotherapy biotech company focused on developing innovative treatments for cancer, particularly targeting significant unmet medical needs. The company has established a robust pipeline of therapies, including 'off-the-shelf' vaccines and highly specific monoclonal antibodies. Their advanced therapeutic vaccine programs, such as SCOPE and ModiFY, have demonstrated promising efficacy in Phase 2 trials, particularly in treating metastatic melanoma and various solid tumors. The SCIB1/iSCIB1+ DNA vaccine, for instance, is designed to elicit strong immune responses by encoding specific epitopes from melanoma antigens, and it has shown favorable safety profiles when combined with standard checkpoint inhibitors.

Scancell's technology platforms include ImmunoBody®, Moditope®, and GlyMab®, each targeting different aspects of cancer immunotherapy. The ImmunoBody® platform utilizes DNA vaccines that express cancer antigens to stimulate immune responses, while Moditope® focuses on peptide vaccines that target post-translational modifications found in tumors. GlyMab® involves the development of high-affinity monoclonal antibodies that specifically target unique glycan structures on tumor cells. Together, these technologies aim to harness the body's adaptive immune response to effectively combat cancer, with a commitment to improving patient outcomes through innovative and safe therapeutic options.

United Kingdom

Scancell is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

We have developed a pipeline of ‘off-the-shelf’ vaccines which induce immune responses and highly tumour specific monoclonal antibodies that redirect immune cells or drugs. Our advanced therapeutic vaccine programmes, SCOPE and ModiFY, have shown promising efficacy in Phase 2 trials, demonstrating long-term survival in metastatic melanoma and a broad range of solid tumours.

Scancell Ltd

Company Details